These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23582367)

  • 41. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
    Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
    J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray.
    Möllerström E; Kovács A; Lövgren K; Nemes S; Delle U; Danielsson A; Parris T; Brennan DJ; Jirström K; Karlsson P; Helou K
    BMC Cancer; 2010 Jun; 10():296. PubMed ID: 20553615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Robertson S; Acs B; Lippert M; Hartman J
    Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.
    Ekholm M; Beglerbegovic S; Grabau D; Lövgren K; Malmström P; Hartman L; Fernö M
    Histopathology; 2014 Aug; 65(2):252-60. PubMed ID: 24527721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.
    Tökés AM; Szász AM; Geszti F; Lukács LV; Kenessey I; Turányi E; Meggyesházi N; Molnár IA; Fillinger J; Soltész I; Bálint K; Hanzély Z; Arató G; Szendröi M; Kulka J
    J Clin Pathol; 2015 Apr; 68(4):274-82. PubMed ID: 25595275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients.
    Golmohammadi R; Pejhan A
    J Pak Med Assoc; 2012 Sep; 62(9):871-5. PubMed ID: 23139965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T-box transcription factor 21 expression in breast cancer and its relationship with prognosis.
    Yu H; Yang J; Jiao S; Li Y; Zhang W; Wang J
    Int J Clin Exp Pathol; 2014; 7(10):6906-13. PubMed ID: 25400774
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.
    Cakir A; Gonul II; Uluoglu O
    Diagn Pathol; 2012 Oct; 7():145. PubMed ID: 23082819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
    Reyal F; Bollet MA; Caly M; Gentien D; Carpentier S; Peyro-Saint-Paul H; Pierga JY; Cottu P; Dieras V; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X
    PLoS One; 2012; 7(4):e35184. PubMed ID: 22529987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Inflammatory breast carcinoma: towards molecular characterization?].
    Charafe-Jauffret E; Tarpin C; Ginestier C; Bertucci F; Penault-Llorca F; Xerri L; Birnbaum D; Viens P; Hassoun J; Jacquemier J
    Ann Pathol; 2003 Dec; 23(6):564-9. PubMed ID: 15094594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.
    Zaguirre K; Kai M; Kubo M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Morisaki T; Mori H; Oda Y; Chen S; Moriyama T; Shimizu S; Nakamura M
    Cancer Med; 2021 Mar; 10(5):1605-1613. PubMed ID: 33452761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
    Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
    Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three molecular classifications surrogate to four immunohistochemical markers in 374 invasive breast carcinomas with long follow-up: which is better?
    Ruiz Martín J; Pérez Sánchez C; de las Heras Camino A
    Pathol Res Pract; 2013 Jun; 209(6):337-44. PubMed ID: 23582367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
    Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
    J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.